JP
RIGL icon

John Paulson’s Rigel Pharmaceuticals RIGL Stock Holding History

John Paulson’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66,206
Closed -$1.81M – 81
2017
Q2 		$1.81M Buy
66,206
+11,206
+20% +$307K 0.02% 93
2017
Q1 		$1.82M Buy
55,000
+16,230
+42% +$414K 0.02% 85
2016
Q4 		$923K Sell
38,770
-41,730
-52% -$1.2M 0.01% 93
2016
Q3 		$2.95M Sell
80,500
-19,470
-19% -$558K 0.03% 81
2016
Q2 		$2.23M Hold
99,970
– – 0.02% 72
2016
Q1 		$2.08M Buy
99,970
+47,100
+89% +$1.16M 0.02% 81
2015
Q4 		$1.6M Buy
+52,870
New +$1.6M 0.01% 69

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

John Paulson's RIGL Position: Q3 2017 in Review

John Paulson sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 66,206 shares — an estimated $1.81M sold.

John Paulson first reported a position in RIGL in Q4 2015 and held it in 7 quarters. The position peaked at $2.95M in Q3 2016. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • John Paulson reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • John Paulson sold 66,206 Rigel Pharmaceuticals shares in Q3 2017, an estimated $1.81M.
  • John Paulson first reported a position in Rigel Pharmaceuticals in Q4 2015 and held it in 7 quarters.
  • John Paulson's Rigel Pharmaceuticals position peaked at $2.95M in Q3 2016.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.